NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
24/12/2024
Voltar para busca
Dado oficial do USPTO
POLYPEPTIDE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Snapshot rápido
ST13
US500000079378525Classe
1, 3, 5, 35, 40, 42
Pedido
79378525
Registro
7616806
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
22
Atualização mais recente
03/04/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
1, 3, 5, 35, 40, 42
Data de depósito
05/05/2023
Data de registro
24/12/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
24/12/2024
Última transação
03/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
16
Localização do titular
SE
Examinador
EISNACH, MICHAEL PATRICK
Unidade examinadora
L40
Localização atual
FILE REPOSITORY (FRANCONIA)
Descrição da marca
The mark consists of a stylized atomic model in green. To the right of this design is the wording "POLYPEPTIDE" in black font. The white in the mark is background only and is not claimed as a feature of the mark.
Titulares e representantes
Titulares
Polypeptide Laboratories Holding (PPL) AB
Representantes
Bethany J. Whelan Dority & Manning, P.A.
Classificação técnica
Classes Nice
Classe 1Classe 3Classe 5Classe 35Classe 40Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Biological preparations for use in industry and science; peptides for industrial purposes; oligonucleotides for industrial purposes
Classe 3
Non-medicated soaps; perfumery; essential oils; cosmetics; hair lotions; dentifrices
Classe 5
Synthetic peptides for pharmaceutical purposesfor use in oncologymetabolic disordersneurologygastrointestinal diseasescardiovascularreproductive healthimmune systemnutritional disorders hormonal disordersmusculoskeletal disordersanestheticscnsimmunology for the treatment of obesitydiabetescancerendometriosisup-regulation of growth hormonelipodystrophy in hiv/aidssleeping disordersendometriosisautoimmune diseasesesophageal hemorrhagehypercalcemiadental infiltrationirritable bowel syndromehypotensionachondroplasiamultiple myelomanon-metastatic osteosarcomaerectile dysfunctiondelaying imminent pre-term birthpostpartum hemorrhagespinocerebellar degenerationhypoactive sexual desire disorderosteoporosispost-menopausal osteoporosischronic idiopathic constipationacute decompensated heart failuresepsis and septic shockacute attacks of hereditary angioedemagastrointestinal bleedingtreatment of hiv-1reduction of hiv lipodystrophysevere chronic painchronic immune thrombocytopenic purpuratreatment of anemia associated with kidney diseaseprevention of respiratory distress syndromeprevention of phototoxicitymyocardial infarctiontreatment of refractory hypotension in adults with septic or other distributive shockirritable bowel syndromemyasthenia gravisuremic pruritusrenal puritushepatorenal syndromegrowth hormone related diseasesacromegalyesophageal varicesbed wettingpolyuriahyperuresishemophilia apremature labortocolysisautoimmune diseasesinfantile spasmsrheumatoid arthritismultiple sclerocsishepatitis btreatment of chushing's diseasetreatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumorsdiagnose of somatostatin receptor-positive neuroendocrine tumorsbacterial infectionsviral infectionsfungal infectionscardiovascular diseasesendocrine disordersneurological conditionsallergic reactions plant; synthetic oligonucleotides for pharmaceutical purposes for use in oncologyneurologyrare diseases for the treatment of genetic disordersneurodegenerative diseases and cancer; pharmaceutical and veterinary preparationssynthetic peptides for pharmaceutical and veterinary purposes for fertility control in animalsinduction of ovulation in marescastration of dogsfacilitation of parturition in livestock; biological preparations for medical and veterinary purposespolypetide biochemicals for medical and veterinary purposes for oncologymetabolic disordersneurologygastrointestinal diseasescardiovascularreproductive healthimmune systemnutritional disorders hormonal disordersmusculoskeletal disordersanestheticscnsimmunology for the treatment of obesitydiabetescancerendometriosisup-regulation of growth hormonelipodystrophy in hiv/aidssleeping disordersendometriosisautoimmune diseasesesophageal hemorrhagehypercalcemiadental infiltrationirritable bowel syndromehypotensionachondroplasiamultiple myelomanon-metastatic osteosarcomaerectile dysfunctiondelaying imminent pre-term birthpostpartum hemorrhagespinocerebellar degenerationhypoactive sexual desire disorderosteoporosispost-menopausal osteoporosischronic idiopathic constipationacute decompensated heart failuresepsis and septic shockacute attacks of hereditary angioedemagastrointestinal bleedingtreatment of hiv-1reduction of hiv lipodystrophysevere chronic painchronic immune thrombocytopenic purpuratreatment of anemia associated with kidney diseaseprevention of respiratory distress syndromeprevention of phototoxicitymyocardial infarctiontreatment of refractory hypotension in adults with septic or other distributive shockirritable bowel syndromemyasthenia gravisuremic pruritusrenal puritushepatorenal syndromegrowth hormone related diseasesacromegalyesophageal varicesbed wettingpolyuriahyperuresishemophilia apremature labortocolysisautoimmune diseasesinfantile spasmsrheumatoid arthritismultiple sclerocsishepatitis btreatment of chushing's diseasetreatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumorsdiagnose of somatostatin receptor-positive neuroendocrine tumorsbacterial infectionsviral infectionsfungal infectionscardiovascular diseasesendocrine disordersneurological conditionsallergic reactions plant; medicated dandruff and hair loss shampoosmedicated hair lotions for treating dandruff hair loss and hair damagemedicated soap cleansers for the skinmedicated cosmeticsnamely creams for treating acneirritateditchinginflamed skinrepairing skin damage and promoting wound healing; medical being medicated hair lotion; medicated soap; sanitary preparations for medical purposes; medicated and sanitizing soaps and detergents; dietetic substances in the nature of protein dietary supplements; protein nutritional supplements; collagen dietary supplements; collagen nutritional supplements; collagen peptide dietary supplements; collagen peptide nutritional supplements adapted for medical use; food for babies; dietetic food adapted for medical use; dietetic food adapted for veterinary use; plasters for medical purposes; materials for dressingsmedical dressings; material for stopping teeth; dental wax; disinfectants; preparations for destroying vermin; fungicides; herbicides; vaccines
Classe 35
Advertising services; business administration; business management; providing office function
Classe 40
Custom manufacturing services for others in the field of peptide and olignuclotide manufacturing
Classe 42
Research and development services relating to vaccines; product research and development services; research and development services in the field of peptide and oligonucelotide manufacturing
Publicações
Histórico de despachos e eventos da marca no USPTO.
22 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
24/12/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
22/10/2024
PUBO
PUBLISHED FOR OPPOSITION
22/10/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/10/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
16/09/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
16/09/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
16/09/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
16/09/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
16/09/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
28/08/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
28/08/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
28/08/2024
RFNT
REFUSAL PROCESSED BY IB
19/03/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
28/02/2024
RFRR
REFUSAL PROCESSED BY MPU
28/02/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/02/2024
CNRT
NON-FINAL ACTION WRITTEN
06/02/2024
DOCK
ASSIGNED TO EXAMINER
31/01/2024
MAFR
APPLICATION FILING RECEIPT MAILED
22/09/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
18/09/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
14/09/2023
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace POLYPEPTIDE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.